Zepbound ( tirzepatide ) takes this one step further by activating not only the GLP-1 receptor but also the GIP receptor, which may enhance its effects on both weight reduction and blood sugar control
Early studies 7 of BPC-157 report that its safety profile and systemic cytoprotective potential are supported by the reported lack of adverse effects in a number of organ systems, including the brain, heart, lungs, liver, kidneys, and gastrointestinal tract
It targets the mitochondria themselves, the structures inside your cells that produce the energy your body runs on
For patients with mild renal insufficiency: (creatinine clearance [CrCl] 50 mL/min, approximately corresponding to serum creatinine levels of 1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin : When JANUVIA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia
Orforgliprons approval is the clearest signal yet that metabolic care is shifting toward broad, affordable access
Dispose of the needle immediately in a sharps container
